List of Excipients in Branded Drug ATRIPLA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Gilead Sciences LLC	ATRIPLA	efavirenz, emtricitabine, and tenofovir disoproxil fumarate	15584-0101	CELLULOSE, MICROCRYSTALLINE
Gilead Sciences LLC	ATRIPLA	efavirenz, emtricitabine, and tenofovir disoproxil fumarate	15584-0101	CROSCARMELLOSE SODIUM
Gilead Sciences LLC	ATRIPLA	efavirenz, emtricitabine, and tenofovir disoproxil fumarate	15584-0101	FERRIC OXIDE RED
Gilead Sciences LLC	ATRIPLA	efavirenz, emtricitabine, and tenofovir disoproxil fumarate	15584-0101	FERROSOFERRIC OXIDE
Gilead Sciences LLC	ATRIPLA	efavirenz, emtricitabine, and tenofovir disoproxil fumarate	15584-0101	HYDROXYPROPYL CELLULOSE
Gilead Sciences LLC	ATRIPLA	efavirenz, emtricitabine, and tenofovir disoproxil fumarate	15584-0101	MAGNESIUM STEARATE

Atripla Excipient Strategy and Commercial Opportunities in Fixed-Dose HIV Therapy

Last updated: August 27, 2026

Atripla is a once-daily, immediate-release tablet combining efavirenz, emtricitabine, and tenofovir disoproxil fumarate. Its excipient platform is conventional for a high-dose oral solid: direct-compression or compressed-granulation aids, superdisintegrants, a surfactant, lubricant, and a film coat. The strongest commercial opportunities are in generic substitution, regional supply, excipient optimization, and alternative fixed-dose combinations rather than in new Atripla-branded innovation.

What is Atripla and which excipients does it contain?

Atripla contains 600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, equivalent to approximately 245 mg tenofovir disoproxil. The total active pharmaceutical ingredient load is approximately 1.1 grams per tablet before excipients and coating.

The FDA-approved product is an immediate-release, film-coated tablet intended for once-daily oral administration.[1]

Component	Function in the Atripla tablet
Efavirenz	Non-nucleoside reverse transcriptase inhibitor
Emtricitabine	Nucleoside reverse transcriptase inhibitor
Tenofovir disoproxil fumarate	Nucleotide reverse transcriptase inhibitor
Microcrystalline cellulose	Diluent and compression aid
Hydroxypropyl cellulose	Binder and granulation aid
Croscarmellose sodium	Superdisintegrant
Sodium starch glycolate	Superdisintegrant
Sodium lauryl sulfate	Wetting and dissolution aid
Magnesium stearate	Lubricant
Colloidal silicon dioxide, where included in the approved presentation	Glidant and flow aid
Hypromellose	Film-coating polymer
Titanium dioxide	Opacifier and pigment
Triacetin	Film-coating plasticizer
FD&C Blue No. 2 aluminum lake	Colorant

The precise inactive-ingredient declaration should be taken from the applicable country-specific label because excipient lists and manufacturing presentations can differ between jurisdictions.[1,2]

Why does Atripla require a complex excipient platform?

Atripla combines three chemically different active ingredients in a high-load tablet. The formulation must address powder flow, content uniformity, compaction, disintegration, dissolution, moisture control, and tablet size.

Efavirenz is poorly water soluble and can create dissolution constraints. Emtricitabine is relatively water soluble, while tenofovir disoproxil fumarate has different compression and stability behavior. A formulation that performs well for one active may compromise another.

The principal formulation challenges are:

1. Achieving uniform distribution of three active ingredients across a large tablet.
2. Maintaining rapid and reproducible dissolution for efavirenz.
3. Preventing over-lubrication from magnesium stearate, which can slow dissolution.
4. Controlling moisture because tenofovir disoproxil fumarate is susceptible to degradation pathways.
5. Managing tablet hardness without impairing disintegration.
6. Producing a tablet that remains acceptable for long-term once-daily use.

The combination of two superdisintegrants, a binder, a surfactant, and a high-load cellulose diluent indicates that the product was engineered around robust disintegration and dissolution rather than a minimal-excipient formulation.

What is the commercial role of each Atripla excipient?

Microcrystalline cellulose

Microcrystalline cellulose provides bulk, compressibility, and mechanical strength. It is commercially important because the tablet has a high active load and must remain compact enough for once-daily dosing.

Potential optimization areas include:

• Grade selection for compactibility and disintegration.
• Moisture-content control.
• Particle-size distribution.
• Substitution with silicified microcrystalline cellulose.
• Co-processing with mannitol or other compression aids.

A generic manufacturer can use a different grade or supplier if the finished product meets quality and bioequivalence requirements.

Croscarmellose sodium and sodium starch glycolate

Using two superdisintegrants provides formulation flexibility but increases sensitivity to grade, particle size, water uptake, and blending order. A manufacturer may attempt to reduce one or both components, but this can affect dissolution after compression or storage.

Commercial opportunities exist for excipient suppliers that can provide:

• Consistent swelling performance.
• Low microbial burden.
• Controlled particle morphology.
• Better performance at lower use levels.
• Validated supply for large-scale generic production.

Sodium lauryl sulfate

Sodium lauryl sulfate improves wetting of hydrophobic efavirenz and can support dissolution. It can also create risks related to sensitivity, impurity control, foaming during processing, and possible interaction with other formulation components.

Alternative wetting strategies may include poloxamers, sodium docusate, surfactant blends, or particle-engineering approaches. Any substitution must be evaluated against dissolution profiles, impurity formation, and comparative bioavailability.

Hydroxypropyl cellulose

Hydroxypropyl cellulose acts primarily as a binder. It supports granule strength and tablet integrity but can slow disintegration or alter dissolution if used at excessive concentration.

A generic formulation may use povidone, copovidone, pregelatinized starch, or a different hydroxypropyl cellulose grade. The opportunity is strongest where a supplier can improve processing efficiency without changing the final release profile.

Magnesium stearate

Magnesium stearate is a conventional lubricant. Its concentration and blending time are critical. Excessive lubrication can reduce tablet tensile strength and retard water penetration.

Manufacturers may evaluate:

• Lower lubricant concentration.
• Shorter lubrication time.
• Alternative lubricants.
• Optimized lubricant particle size.
• Continuous blending approaches.

This area offers process-cost savings but usually provides limited standalone exclusivity because lubricant selection is rarely a strong patent barrier.

Film-coating materials

The hypromellose, titanium dioxide, triacetin, and blue colorant system provides appearance, swallowability, protection from handling, and product identification.

Commercial opportunities include:

• Lower-weight film coating.
• Faster coating cycles.
• Aqueous coating systems with lower process burden.
• Pigment systems that reduce color variation.
• Packaging and coating strategies that improve moisture protection.

A different color or coating composition may be acceptable for a generic product if it satisfies regulatory requirements and does not create confusion with the reference product.

What formulation patents protect Atripla?

The principal intellectual-property value historically associated with Atripla has been the combination of known antiretroviral agents, manufacturing processes, and product-specific regulatory rights. The FDA label does not establish patent ownership for individual excipients.[1]

Excipient selection alone is unlikely to provide durable exclusivity because the listed materials are widely used pharmaceutical excipients. Commercial protection would more likely arise from:

• A specific ratio or physical arrangement of the three active ingredients.
• A process that improves efavirenz dissolution.
• Particle-size control or solid-dispersion technology.
• A moisture-stabilized tablet or package.
• A particular manufacturing sequence.
• A clinically supported alternative dosage regimen.
• A new formulation with reduced food effect or improved tolerability.

An excipient patent directed only to microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, hydroxypropyl cellulose, or magnesium stearate would face substantial novelty and obviousness challenges unless tied to a specific composition or measurable performance result.

When did Atripla lose exclusivity?

Atripla's U.S. market protection has been affected by several layers of exclusivity and patent rights rather than one single expiration date. The core product was approved by the FDA in July 2006.[3]

Event	Approximate timing	Commercial significance
FDA approval of Atripla	July 2006	Established the fixed-dose reference product
U.S. generic pathway opened through patent and settlement developments	Early 2010s	Increased future substitution risk
Core combination exclusivity and patent barriers began expiring	Late 2010s to early 2020s	Reduced branded protection
Generic and public-sector competition expanded	2010s onward	Pressured volume and price
U.S. branded commercial relevance declined	2020s	Limited opportunity for premium Atripla pricing

Exact patent expiry depends on the specific listed patent, jurisdiction, pediatric extensions, settlement terms, and product presentation. The FDA Orange Book remains the controlling source for current U.S. listed patents and exclusivity status.[4]

What is the Orange Book status of Atripla?

Atripla is an FDA-approved small-molecule combination product and therefore falls within the Orange Book framework for approved drug products and listed patents.[4] It is not a biologic and does not use the Purple Book biosimilar system.

An abbreviated new drug application for an Atripla-equivalent product would generally rely on an ANDA pathway with paragraph certifications addressing any relevant listed patents. A generic applicant must also establish pharmaceutical equivalence, bioequivalence, manufacturing quality, and compliance with labeling requirements.

The Orange Book status should be assessed by:

• Active ingredient combination.
• Strength and dosage form.
• Current reference-listed-drug designation.
• Listed patents and delisting history.
• Pediatric exclusivity.
• Any approved generic equivalents.

Which companies have challenged Atripla patents?

Multiple generic manufacturers and public-health suppliers have pursued equivalent products or related antiretroviral combinations as Atripla's protection declined. The relevant competitive field has included large generic companies, Indian manufacturers, and suppliers focused on Global Fund and other public-sector procurement channels.

A definitive current list of paragraph IV filers and litigation defendants must be taken from the FDA Orange Book, FDA litigation records, and federal court dockets for the relevant patent numbers. Generic competition has also arisen outside the United States through national approval systems that do not mirror the U.S. paragraph IV process.

The major commercial point is that Atripla's active ingredients are individually mature and widely manufactured. The technical barrier is therefore lower than for a new chemical entity, although the combination's high tablet load and dissolution requirements remain meaningful development hurdles.

Does Atripla face biosimilar risk?

No. Atripla is a chemically synthesized small-molecule tablet, not a biologic. Biosimilar legislation does not apply.

The relevant risks are:

• ANDA-based generic substitution.
• National generic approvals outside the United States.
• Fixed-dose combinations containing the same active ingredients.
• Therapeutic substitution to newer tenofovir alafenamide or integrase-inhibitor regimens.
• Public-sector procurement substitution.

The last risk is commercially important. Even where no direct Atripla-equivalent is available, treatment programs can substitute another complete antiretroviral regimen.

What generic launch scenarios exist for Atripla?

Scenario 1: Direct immediate-release generic

This is the most straightforward opportunity. The product would match the reference product's active ingredients, strengths, route, and dosage form while using a permitted alternative excipient system.

Key development work includes:

• Comparative dissolution across media.
• Fed and fasting bioequivalence.
• Stability under long-term and accelerated conditions.
• Impurity monitoring for tenofovir disoproxil fumarate.
• Efavirenz particle-size and wetting control.
• Tablet robustness and coating performance.

Scenario 2: Low-cost public-sector product

A supplier may target national programs, tenders, and low-income markets. The primary competitive variables are manufacturing cost, regulatory registrations, supply reliability, packaging, and procurement eligibility.

Excipient savings can contribute to margin, but active pharmaceutical ingredient cost, quality systems, freight, and tender pricing usually have greater financial impact.

Scenario 3: Reformulated fixed-dose combination

A new formulation could seek improved dissolution, smaller tablet size, reduced food-effect variability, or better tolerability. A 505(b)(2) pathway may be relevant only if the product introduces a meaningful formulation or clinical distinction and cannot be adequately approved through a conventional ANDA.

A reformulation would face direct competition from modern regimens, particularly integrase-inhibitor combinations. That limits the commercial value of an incremental Atripla formulation.

Scenario 4: Regional licensing and contract manufacturing

Companies with established HIV registrations can license formulation dossiers or manufacture for regional partners. Attractive territories are those with:

• Large treated HIV populations.
• Active tender markets.
• Local registration pathways.
• Limited access to premium newer regimens.
• Demand for once-daily fixed-dose products.

The strongest licensing proposition is usually regulatory and supply execution, not proprietary excipient technology.

How does Atripla compare with newer HIV fixed-dose combinations?

Product or regimen	Principal commercial position	Excipient opportunity
Atripla	Mature efavirenz-based once-daily combination	Low-cost generic, public-sector supply, formulation efficiency
Complera/Eviplera	Rilpivirine-based fixed-dose combination	Similar high-load tablet and food-administration considerations
Odefsey	Tenofovir alafenamide-based combination	Greater relevance in markets prioritizing improved tenofovir exposure
Biktarvy	Bictegravir-based combination	Stronger modern branded positioning; limited Atripla-style substitution opportunity
Triumeq	Dolutegravir-based combination	Competes on efficacy, tolerability, and treatment guidelines
Generic efavirenz combinations	Price-driven alternatives	High-volume regional and tender opportunity

Treatment guidelines have generally moved away from efavirenz-based first-line therapy where integrase-inhibitor regimens are accessible. This reduces the premium opportunity for Atripla but does not eliminate demand in price-sensitive markets.

What manufacturing and intellectual-property barriers remain?

Atripla has no meaningful biosimilar barrier, and its excipients are broadly available. The remaining barriers are technical, regulatory, and operational:

• Reproducing efavirenz dissolution.
• Controlling high-dose tablet compression.
• Managing API particle-size differences.
• Demonstrating bioequivalence.
• Maintaining stability in hot and humid climates.
• Qualifying multiple excipient and API suppliers.
• Meeting country-specific HIV product requirements.
• Securing reliable supply for tenders.

Packaging can be commercially important. High-barrier blister materials, desiccant systems, and moisture-controlled bottles may reduce degradation risk, particularly in tropical markets. Packaging improvements can be protectable through process or package patents, but they are more often used as quality and cost differentiators than as durable exclusivity tools.

How strong is the Atripla patent estate?

The patent estate is commercially weak relative to newly launched branded medicines because:

• The active ingredients are old and widely available.
• The core fixed-dose concept is mature.
• The listed excipients are standard.
• Direct generic and regional competition exists.
• Newer HIV regimens have reduced clinical demand.

Potentially stronger rights would be narrow patents covering a specific dissolution-enhancing composition, manufacturing process, particle-engineering method, or stability package. Their value would depend on claim scope, validity, enforceability, and whether a generic can design around them.

What is the revenue exposure from Atripla competition?

Revenue exposure is concentrated in residual branded sales, mature-market prescriptions, and lower-income-country supply channels. Generic entry can reduce price rapidly, while therapeutic switching can reduce volume even before direct generic substitution.

A commercial model should separate:

1. U.S. branded Atripla revenue.
2. International branded revenue.
3. Generic and authorized-generic revenue.
4. Public-sector tender volume.
5. API and finished-dose manufacturing economics.
6. Revenue displaced by newer antiretroviral combinations.

For an excipient supplier, the addressable value is much smaller than total drug revenue. The practical opportunity lies in recurring supply contracts, dual-source qualification, and technical support for generic manufacturers.

Key Takeaways

• Atripla is a high-dose, immediate-release tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate.
• Its excipient system is conventional but technically balanced around compression, wetting, dissolution, disintegration, and stability.
• The most commercially relevant excipient functions involve efavirenz wetting, tablet compactibility, superdisintegration, lubrication control, and moisture protection.
• Individual Atripla excipients are unlikely to provide meaningful exclusivity.
• Generic substitution, public-sector tenders, regional licensing, and contract manufacturing are the main opportunities.
• Atripla has no biosimilar risk; its principal threats are ANDA generics and therapeutic switching to newer integrase-inhibitor regimens.
• A reformulated Atripla product would face a limited premium opportunity unless it provides a clear clinical, dosing, stability, or cost advantage.
• Current patent and Orange Book conclusions require review of the specific jurisdiction, product presentation, and listed patent records.

FAQs

Can Atripla be reformulated with fewer excipients?

Yes. A generic manufacturer can use a different excipient system if the product meets pharmaceutical equivalence, bioequivalence, quality, stability, and labeling requirements. Reducing excipients can affect efavirenz dissolution and tablet robustness.

Which excipient is most important for efavirenz dissolution?

Sodium lauryl sulfate is a principal wetting aid in the labeled formulation, but efavirenz particle size, dispersion, granulation, compression, and surfactant concentration also influence dissolution.

Is Atripla suitable for a 505(b)(2) product?

Usually, a direct equivalent would be better suited to an ANDA. A 505(b)(2) strategy would require a meaningful formulation, dosing, safety, or clinical distinction that cannot be adequately addressed through the ANDA pathway.

Are Atripla excipients suitable for tropical markets?

They can be, but stability must be demonstrated under applicable long-term and accelerated conditions. Moisture-control packaging and tight API impurity specifications are important for hot and humid regions.

What is the best commercial entry point for an Atripla-related business?

The strongest entry points are low-cost generic supply, public-sector procurement, regional licensing, contract manufacturing, and excipient or process solutions that improve dissolution, tablet yield, or stability without increasing product cost.

References

1. U.S. Food and Drug Administration. (2020). Atripla prescribing information. Gilead Sciences, Inc.

2. National Library of Medicine. (n.d.). DailyMed: Atripla, efavirenz/emtricitabine/tenofovir disoproxil fumarate tablet, film coated. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2006, July 12). FDA approves Atripla, first once-daily three-drug combination treatment for HIV-1 infection. FDA.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.